scholarly journals Dietary Phytochemicals in Zinc Homeostasis: A Strategy for Prostate Cancer Management

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1867
Author(s):  
Chandra K. Singh ◽  
Gagan Chhabra ◽  
Arth Patel ◽  
Hao Chang ◽  
Nihal Ahmad

Studies have suggested an important role of the trace element zinc (Zn) in prostate biology and functions. Zn has been shown to exist in very high concentrations in the healthy prostate and is important for several prostatic functions. In prostate cancer (PCa), Zn levels are significantly decreased and inversely correlated with disease progression. Ideally, restoration of adequate Zn levels in premalignant/malignant prostate cells could abort prostate malignancy. However, studies have shown that Zn supplementation is not an efficient way to significantly increase Zn concentrations in PCa. Based on a limited number of investigations, the reason for the lower levels of Zn in PCa is believed to be the dysregulation of Zn transporters (especially ZIP and ZnT family of proteins), metallothioneins (for storing and releasing Zn), and their regulators (e.g., Zn finger transcription factor RREB1). Interestingly, the level of Zn in cells has been shown to be modulated by naturally occurring dietary phytochemicals. In this review, we discussed the effect of selected phytochemicals (quercetin, resveratrol, epigallocatechin-3-gallate and curcumin) on Zn functioning and proposes that Zn in combination with specific dietary phytochemicals may lead to enhanced Zn bioaccumulation in the prostate, and therefore, may inhibit PCa.

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Chi-Ju Kim ◽  
Liang Dong ◽  
Sarah Amend ◽  
Yoon-Kyoung Cho ◽  
Kenneth Pienta

Liquid biopsy has emerged as a complement to invasive tissue biopsy to guide cancer diagnosis and treatment. The common liquid biopsy biomarkers are circulating tumor cells (CTCs), extracellular vesicles (EVs),...


2012 ◽  
Vol 9 (2) ◽  
pp. 94-101 ◽  
Author(s):  
Edward M. Lawrence ◽  
Vincent J. Gnanapragasam ◽  
Andrew N. Priest ◽  
Evis Sala

Urology ◽  
2007 ◽  
Vol 69 (2) ◽  
pp. 203-209 ◽  
Author(s):  
S. Sivalingam ◽  
J. Oxley ◽  
J.L. Probert ◽  
J.U. Stolzenburg ◽  
H. Schwaibold

2010 ◽  
Vol 17 (1) ◽  
pp. F1-F17 ◽  
Author(s):  
Valeria Coppola ◽  
Ruggero De Maria ◽  
Désirée Bonci

Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tools are needed to predict disease severity, choose among the available treatments and establish more effective therapies for advanced prostate cancer. In the last few years, compelling evidence has documented the role of microRNAs as new broad-spectrum oncogenes or tumour suppressor genes, thus their use as diagnostic, prognostic and therapeutic biomolecules is envisaged. This review extensively and critically summarizes the current knowledge about microRNA deregulation in prostate cancer disease, underlining present limits and future perspectives.


2009 ◽  
Vol 30 (5) ◽  
pp. 325 ◽  
Author(s):  
Paula Lindholm ◽  
Marko Seppänen ◽  
Heikki Minn

2019 ◽  
Vol 7 (6) ◽  
Author(s):  
Bital Savir-Baruch ◽  
Funmilayo Tade ◽  
Elizabeth Henry ◽  
Ari Goldberg ◽  
Lovrec Petra ◽  
...  

2016 ◽  
Vol 32 (7) ◽  
pp. 956-957 ◽  
Author(s):  
Zdzislaw Zuchora ◽  
Mark Browne ◽  
Niall Colgan

2017 ◽  
pp. 33-50 ◽  
Author(s):  
Benjamin Taylor ◽  
Anna Paschali ◽  
Vineet Pant ◽  
Ishita B. Sen ◽  
Gary Cook

1970 ◽  
Vol 2 (1) ◽  
Author(s):  
SHAH SIA

Prostate cancer (PCa) treatment has seen several important developments over the last few decades in the form of improved surgical methods and advanced radiotherapy techniques but androgen deprivation therapy (ADT) still remains the cornerstone of medical management of this common male malignancy. The discovery of androgen-dependent nature of PCa about three-quarters of a century ago was a turning point that has since led to the development of various pharmacological agents which rely on the basic principle of hormonal manipulation in the form of ADT to alter disease progression. Initially employed for metastatic disease only, ADT for PCa in the current clinical practice finds use multiple stages of the disease. The present review summarises the chronological evolution of agents used for hormonal manipulation in the management of PCa, highlighting the pros and cons of each and sheds light on the potential future advances in this area.


Sign in / Sign up

Export Citation Format

Share Document